New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
10:06 EDTDVA, FMSMedicare urged by auditor to recalculate dialysis payments
An updated report released by the Health and Human Services Departmentís Inspector General recommended that the Centers for Medicare & Medicaid Services redetermine the basis of the end stage renal disease, or ESRD, base rate to reflect current trends in drug acquisition costs, as required by law; distinguish payments in the ESRD base rate between independent and hospital-based dialysis facilities; and consider updating the ESRD payment bundle using a factor that takes into account drug acquisition costs. "CMS did not explicitly state whether it concurred with our first recommendation, did not concur with our second recommendation, and concurred with our third recommendation," the report stated. DaVita (DVA) and Fresenius Medical (FMS) are publicly-traded companies that operate dialysis centers. Reference Link
News For DVA;FMS From The Last 14 Days
Check below for free stories on DVA;FMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
10:02 EDTDVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:43 EDTDVADaVita downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
July 18, 2014
16:05 EDTDVADaVita says CEO of HealthCare Partners subsidiary to step down
DaVita HealthCare Partners announced that HealthCare Partners, or HCP, president and CEO Dr. Craig Samitt is stepping down from HCP effective August 1. Kent Thiry, co-chairman and CEO of DaVita HealthCare Partners, will take over the role of CEO of HCP, working in tandem with the office of Chief Medical Officer.
July 17, 2014
07:00 EDTDVA, FMSFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use